Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

被引：67

作者：

Eisen, Andrea ^{[1
,2
]}

Somerfield, Mark R. ^{[3
]}

Accordino, Melissa K. ^{[4
]}

Blanchette, Phillip S. ^{[5
]}

Clemons, Mark J. ^{[6
]}

Dhesy-Thind, Sukhbinder ^{[7
]}

Dillmon, Melissa S. ^{[8
]}

D'Oronzo, Stella ^{[9
]}

Fletcher, Glenn G. ^{[10
]}

Frank, Elizabeth S.

Hallmeyer, Sigrun ^{[11
]}

Makhoul, Issam ^{[12
]}

Moy, Beverly ^{[13
]}

Thawer, Alia ^{[1
,2
]}

Wu, Joy Y. ^{[14
]}

Van Poznak, Catherine H. ^{[15
]}

机构：

[1] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[2] Ontario Hlth, Toronto, ON, Canada

[3] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA

[4] Columbia Univ, HICCC, New York, NY USA

[5] London Hlth Sci Ctr, London, ON, Canada

[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[7] Juravinski Canc Ctr, Hamilton, ON, Canada

[8] Harbin Clin LLC, Rome, GA USA

[9] Univ Bari Aldo Moro, Bari, Italy

[10] McMaster Univ, Hamilton, ON, Canada

[11] Advocate Lutheran Gen Hosp, Prospect Heights, IL USA

[12] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

[13] Massachusetts Gen Hosp, Boston, MA 02114 USA

[14] Stanford Univ, Palo Alto, CA 94304 USA

[15] Univ Michigan, Ann Arbor, MI 48109 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 07期

关键词：

AMERICAN SOCIETY; CARE ONTARIO; THERAPY;

D O I：

10.1200/JCO.21.02647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline. METHODS An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. RESULTS Four articles met eligibility criteria and form the evidentiary basis for revision of the previous recommendations. RECOMMENDATIONS Adjuvant bisphosphonate therapy should be discussed with all postmenopausal patients (natural or therapy-induced) with primary breast cancer, irrespective of hormone receptor status and human epidermal growth factor receptor 2 status, who are candidates to receive adjuvant systemic therapy. Adjuvant bisphosphonates, if used, are not substitutes for standard anticancer modalities. The benefit of adjuvant bisphosphonate therapy will vary depending on the underlying risk of recurrence and is associated with a modest improvement in overall survival. The NHS PREDICT tool provides estimates of the benefit of adjuvant bisphosphonate therapy and may aid in decision making. Factors influencing the decision to recommend adjuvant bisphosphonate use should include patients' risk of recurrence, risk of side effects, financial toxicity, drug availability, patient preferences, comorbidities, and life expectancy. When an adjuvant bisphosphonate is used to prevent breast cancer recurrence, the therapeutic options recommended by the Panel include oral clod ronate, oral ibandronate, and intravenous zoledronic acid. The Panel supports starting bisphosphonate therapy early, consistent with the points outlined in the parent CCO-ASCO guideline; this is a consensus recommendation. The Panel does not recommend adjuvant denosumab to prevent breast cancer recurrence, because studies did not show a consistent reduction of breast cancer recurrence in any subset of those with early-stage breast cancer. (C) 2022 by American Society of Clinical Oncology

引用

页码：787 / 800

页数：17

共 28 条

[1]

Alpert AB, 2021, ASCO Daily News, January 19

[2] I'm not putting on that floral gown: Enforcement and resistance of gender expectations for transgender people with cancer [J].

Alpert, Ash B. ;

Gampa, Vikas ;

Lytle, Megan C. ;

Manzano, Charlie ;

Ruddick, Roman ;

Poteat, Tonia ;

Quinn, Gwendolyn P. ;

Kamen, Charles S. .

PATIENT EDUCATION AND COUNSELING, 2021, 104 (10) :2552-2558

[3]

[Anonymous], UCSF Transgender Care

[4] St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [J].

Balic, Marija ;

Thomssen, Christoph ;

Wuerstlein, Rachel ;

Gnant, Michael ;

Harbeck, Nadia .

BREAST CARE, 2019, 14 (02) :103-110

[5] Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter? [J].

Brufsky, Adam ;

Mathew, Aju .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (07) :659-660

[6] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Cardoso, F. ;

Kyriakides, S. ;

Ohno, S. ;

Penault-Llorca, F. ;

Poortmans, P. ;

Rubio, I. T. ;

Zackrisson, S. ;

Senkus, E. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220

[7] Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J].

Coleman, R. ;

Powles, T. ;

Paterson, A. ;

Gnant, M. ;

Anderson, S. ;

Diel, I. ;

Gralow, J. ;

von Minckwitz, G. ;

Moebus, V. ;

Bergh, J. ;

Pritchard, K. I. ;

Bliss, J. ;

Cameron, D. ;

Evans, V. ;

Pan, H. ;

Peto, R. ;

Bradley, R. ;

Gray, R. ;

Bartsch, R. ;

Dubsky, P. ;

Fesl, C. ;

Fohler, H. ;

Greil, R. ;

Jakesz, R. ;

Lang, A. ;

Luschin-Ebengreuth, G. ;

Marth, C. ;

Mlineritsch, B. ;

Samonigg, H. ;

Singer, C. F. ;

Steger, G. G. ;

Stoeger, H. ;

Olivotto, I. ;

Ragaz, J. ;

Christiansen, P. ;

Ejlertsen, B. ;

Ewertz, M. ;

Jensen, M-B ;

Moller, S. ;

Mouridsen, H. T. ;

Eiermann, W. ;

Hilfrich, J. ;

Jonat, W. ;

Kaufmann, M. ;

Kreienberg, R. ;

Schumacher, M. ;

Blohmer, J. U. ;

Costa, S. D. ;

Eidtmann, H. ;

Gerber, B. .

LANCET, 2015, 386 (10001) :1353-1361

[8] Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [J].

Coleman, Robert ;

Finkelstein, Dianne M. ;

Barrios, Carlos ;

Martin, Miguel ;

Iwata, Hiroji ;

Hegg, Roberto ;

Glaspy, John ;

Montano Perianez, Alvaro ;

Tonkin, Katia ;

Deleu, Ines ;

Sohn, Joohyuk ;

Crown, John ;

Delaloge, Suzette ;

Dai, Tian ;

Zhou, Ying ;

Jandial, Danielle ;

Chan, Arlene .

LANCET ONCOLOGY, 2020, 21 (01) :60-72

[9] Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold? [J].

Desnoyers, Alexandra ;

Amir, Eitan ;

Tannock, Ian F. .

JAMA ONCOLOGY, 2021, 7 (08) :1121-1123

[10] Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline [J].

Dhesy-Thind, Sukhbinder ;

Fletcher, Glenn G. ;

Blanchette, Phillip S. ;

Clemons, Mark J. ;

Dillmon, Melissa S. ;

Frank, Elizabeth S. ;

Gandhi, Sonal ;

Gupta, Rasna ;

Mates, Mihaela ;

Moy, Beverly ;

Vandenberg, Ted ;

Van Poznak, Catherine H. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18) :2062-+

← 1 2 3 →